Large gap with delayed quotes
|
Official
01/15/2025 -
17:55:00
|
Bid
- -
-
|
Bid Volume |
Ask
- -
-
|
Ask Volume |
|---|---|---|---|---|
|
1.77
-0.052
(
-2.85% )
|
-
|
- |
-
|
- |
Analysis date: 14.01.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 13.12.2024.
Interest
Strong
Strong
Strong interest since 14.01.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 20.12.2024 at a price of 1.92.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, at its current price the stock is fairly valued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 10.12.2024), the stock traded above its moving average. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 1.778.
4wk Rel Perf
-13.40%
-13.40%
The four week relative underperformance versus STOXX600 is 13.40%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 10.12.2024.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.11%.
Mkt Cap in $bn
0.16
0.16
With a market capitalization <$2bn, INNATE PHARMA is considered a small-cap stock.
G/PE Ratio
65.30
65.30
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
2.78
2.78
The estimated PE is for the year 2026.
LT Growth
181.22%
181.22%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
3
3
Over the last seven weeks, an average of 3 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
94
94
For 1% of index variation, the stock varies on average by 0.94%.
Correlation
0.24
0.24
Stock movements are strongly independent of index variations.
Value at Risk
0.40
0.40
The value at risk is estimated at EUR 0.40. The risk is therefore 21.86%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
08.04.2014
08.04.2014